Q-Med brings forward the date for the Year-End Report 2010

The Year-End Report 2010 for Q-Med AB will be published at 08.00 a.m. on Monday
January 31, 2011, instead of, as earlier announced, on February 11, 2011.

Galderma Holding AB, a company wholly-owned by Galderma Pharma S.A., announced
on December 13, 2010 a public takeover offer to the shareholders of Q-Med to
tender all of their shares in Q-Med to Galderma.

In the light of this the Board of Q-Med AB considers that it is important that
the shareholders receive information that is as up-to-date as possible with
regard to the company's results and financial position. The Board has therefore
decided to bring forward the time when the company's year-end report for 2010 is
published to 8 a.m. on January 31.



Queries should be addressed to:
Anders Milton, Chairman of the Bid Committee and Director of the Board
Tel: +46 (0) 70-526 46 02



Q-Med provides the information in this press release in accordance with the
Securities Market Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 09.00 (CET) on 25 January, 2011.

Q-Med ABis a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q-Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com Web: www.q-
med.com


[HUG#1482116]